Jaguar Health, Inc. (JAGX)
After hours:
| Previous Close | 5.1300 |
| Open | 5.3000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.5200 - 5.3000 |
| 52 Week Range | 3.0600 - 43.2000 |
| Volume | |
| Avg. Volume | 1,247,041 |
| Market Cap | 22.637M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 0.14 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for ...
- ACCESSWIRE
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at April 2024 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" ...
- ACCESSWIRE
Jaguar Health Reports First Quarter 2024 Financial Results
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 ...
